Sample Cannabis & CBD Report
See how your CYP enzyme genetics affect THC metabolism, CBD processing, side effect risk, and drug interactions from smoked cannabis.
Cannabis & CBD Pharmacogenomics Report
April 2026
How your CYP enzyme genetics affect THC and CBD metabolism
Your Cannabis Metabolism Summary
3 Actionable FindingsYour DNA reveals 3 findings relevant to how your body processes cannabis and CBD, including an elevated CBD side effect risk from a gene-gene interaction.
THC Metabolism Profile — CYP2C9
Moderately Slower THC Metabolism
CYP2C9: *1/*3 (Intermediate Metabolizer)
Your CYP2C9 result indicates moderately reduced enzyme activity. Research suggests that intermediate metabolizers clear THC somewhat more slowly than normal metabolizers, which may result in slightly stronger or longer-lasting effects.
Clinical Context
CYP2C9 handles approximately 70% of THC clearance. Carrying one reduced-function allele (*3) produces a moderate reduction in enzyme activity, leading to measurably higher THC exposure compared to *1/*1 normal metabolizers.
What This Means for You
- THC effects may last somewhat longer than average.
- Be mindful that your response to cannabis may differ from others.
- Mention this result to your healthcare provider if using medical cannabis.
Additional Findings
Moderately Altered CBD Metabolism
CYP2C19: *1/*2
Your CYP2C19 result indicates moderately reduced enzyme activity. Research shows that intermediate metabolizers have measurably different CBD-to-metabolite ratios compared to normal metabolizers.
Full analysis, clinical context, and recommendations in your report
Elevated Risk of CBD Side Effects
CYP3A5: *3/*3
Your combination of CYP3A5 and CYP2C19 results is associated with a significantly higher rate of gastrointestinal side effects from CBD. In a clinical study, individuals with this gene combination experienced diarrhea at a rate of 39%, compared to 7% in those with other genotype combinations.
Full analysis, clinical context, and recommendations in your report
Higher CYP1A2 Inducibility — Smoked Cannabis Interaction
CYP1A2: rs762551 (A/A)
Your CYP1A2 genotype (rs762551 A/A) is associated with higher enzyme inducibility. Smoked cannabis — but not vaped or edible forms — induces CYP1A2 through combustion byproducts (polycyclic aromatic hydrocarbons).
Full analysis, clinical context, and recommendations in your report
3 additional sections including CBD metabolism, gene-gene interaction risk, and smoking interactions in your personalized report
Limitations
- Cannabis pharmacogenomics is an evolving field with fewer clinical trials than pharmaceutical PGx.
- Consumer genotyping chips test a limited set of variants per gene.
- Individual response to cannabis depends on many factors beyond genetics.
- This report is for educational and informational purposes only.
- This report does not recommend or endorse cannabis use.
This is a sample report generated with fictional data for demonstration purposes. Your actual report will reflect your personal genetic results.
Get your personalized cannabis report
Upload your 23andMe or AncestryDNA raw data. Your Cannabis & CBD Report is $29 — one-time, no subscription.
Get Your Cannabis & CBD ReportFree Upload vs. Cannabis & CBD Report
Everyone gets free trait insights after uploading. The Cannabis & CBD Report maps your CYP2C9, CYP2C19, CYP3A5, and CYP1A2 results to cannabis-specific metabolism, side effects, and drug interactions.
Free with upload
- 9 trait insights (caffeine, lactose, etc.)
- CYP2C9 and CYP2C19 metabolizer status
- THC metabolism profile and clearance speed
- CBD metabolism and metabolite ratios
- CYP3A5+CYP2C19 side effect risk assessment
- Smoked cannabis drug interaction analysis
Cannabis & CBD Report
$29- THC metabolism via CYP2C9 with clinical evidence
- CBD metabolism via CYP2C19 with metabolite context
- Gene-gene interaction: CYP3A5 + CYP2C19 side effect risk
- CYP1A2 smoking interaction with affected medications
- PDF download for healthcare provider sharing
- Published research citations for every finding
Cannabis Pharmacogenomics from DNA You Already Have
The Cannabis & CBD Report is $29 using raw data from 23andMe or AncestryDNA. No new sample needed — we analyze the same CYP enzyme variants already in your uploaded file.
This is the same pharmacogenomic science used for FDA-approved medications. The CYP2C9-THC and CYP2C19-CBD relationships are published in peer-reviewed clinical pharmacology journals.
Based on Published Clinical Research
Every finding cites peer-reviewed studies on cannabinoid pharmacogenomics. CYP2C9-THC metabolism data comes from clinical pharmacokinetic trials. The CYP3A5+CYP2C19 interaction comes from a 2026 clinical study with measured adverse event rates.
For educational and informational purposes only. This report does not recommend or endorse cannabis use. See our limitations page for details.
Ready to See Your Cannabis & CBD Results?
Upload your 23andMe or AncestryDNA raw data. Your personalized Cannabis & CBD Report is $29 — one-time, no subscription.